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OBJECTIVES The study was done to determine the role of partial agonist activity in the lack of effectiveness
of the oral GPIIb/IIIa antagonist orbofiban.
BACKGROUND Orbofiban, an oral GPIIb/IIIa antagonist, was found to increase the mortality of patients with
acute coronary syndromes (ACS) in the OPUS-TIMI-16 trial, despite the fact that it is a very
potent anti-platelet agent and that IV agents have proven very effective.
METHODS Patients (n 5 520) with ACS were randomized to orbofiban 30 mg, 40 mg or 50 mg twice
daily or 50 mg once daily or placebo. Platelet activity was assessed in 175 patients by
examining GPIIb/IIIa receptor conformation, expression of CD63 antigen, and platelet
aggregation.
RESULTS Plasma concentrations of orbofiban at the highest dose (74 6 6 ng/ml peak, 61 6 5 ng/ml
trough) exceeded the IC50 for platelet aggregation to adenosine diphosphate (ADP) (29 6
6 ng/ml) and thrombin-activating peptide (61 6 18 ng/ml). Orbofiban induced a confor-
mational change in GPIIb/IIIa detected as the displacement of the monoclonal antibody
mAb2; such conformational changes have been linked to partial agonist activity. Consistent
with this, platelet expression of CD63 ex vivo was significantly increased at five time points
during the study. In vitro, orbofiban increased platelet aggregation to a submaximal
concentration of epinephrine (67 6 19% vs. 27 6 9%, n 5 5) and increased thromboxane
formation when the platelet GPIIb/IIIa were clustered using monoclonal antibodies to the
receptor.
CONCLUSIONS Orbofiban is both an antagonist and a partial agonist of platelet GPIIb/IIIa. At low
concentrations of the drug, this partial agonist activity may enhance platelet aggregation.
Along with suboptimal plasma drug levels, these findings may help explain the lack of efficacy
seen with orbofiban in patients with ACS. (J Am Coll Cardiol 2000;36:1514–9) © 2000 by
the American College of Cardiology
Glycoprotein (GP) IIb/IIIa (platelet fibrinogen receptor)
antagonists are a novel class of antithrombotics that block
fibrinogen binding to platelets and thereby prevent platelet
aggregation (1,2). These compounds have proved effective
in patients with unstable angina or myocardial infarction
(MI) and following coronary angioplasty when administered
as short-term infusions (3). Results of these trials are
consistent with evidence of a role for platelets in unstable
coronary syndromes (4–7). However, GPIIb/IIIa antago-
nists have proved ineffective when administered chronically
as oral compounds in patients presenting with acute coro-
nary syndromes or following coronary angioplasty. Indeed,
in the OPUS-TIMI-16 Phase III trial of the GPIIb/IIIa
antagonist orbofiban, the mortality was increased in patients
on active treatment compared with those on placebo (8).
One factor that may limit the effectiveness of GPIIb/IIIa
antagonists is their propensity to act as partial agonists.
GPIIb/IIIa is one of a family of receptors, the integrins, that
act as receptors for adhesive proteins (1). Upon ligand
binding, integrins transmit signals into cells, which in the
case of GPIIb/IIIa amplify platelet activation (9–12). Al-
though this is most evident with large ligands such as
fibrinogen, small ligands designed as integrin antagonists
trigger similar signals in vitro (13,14), particularly if they
induce extensive conformational changes in the receptor
(15,16). We examined the effects of orbofiban on platelet
function when administered for 84 days in patients present-
ing initially with unstable angina and MI. In addition, we
looked for evidence of partial agonist activity in vitro.
METHODS
Clinical study. The study was established as a Phase II
dose-finding study of orbofiban. The trial was approved by
the Irish Medicines Board, by the Drugs Directorate,
Health Canada, and the institutional review bodies of the
participating hospitals. All patients gave written, informed
consent. Patients were considered eligible for the study if
they had unstable angina (,120 h from last chest pain) or
a recent MI (,120 h). Patients were randomized to placebo
(n 5 101) twice daily, orbofiban 30 mg twice daily (n 5
109), orbofiban 40 mg twice daily (n 5 104), orbofiban
50 mg twice daily (n 5 104) or orbofiban 50 mg once daily
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with a matching placebo in place of the second dose each
day (n 5 102). Treatment was continued for 84 days.
Detailed platelet studies were performed in 175 subjects:
placebo (n 5 36); orbofiban 30 mg twice daily (n 5 34);
orbofiban 40 mg twice daily (n 5 34); orbofiban 50 mg
twice daily (n 5 37); and orbofiban 50 mg once daily (n 5
34). These patients were all the patients enrolled in all
participating Irish and Canadian sites. In addition to the
study medication, patients received 162 mg aspirin daily.
Samples were taken pre-dose and 4 h and 6 h post-dose on
days 1, 28, and 84 (last day) of treatment.
Platelet aggregation. Citrated (3.8%) whole blood was
centrifuged at 850 3 g for 3 min to produce platelet-rich
plasma (PRP). The remaining blood was centrifuged for
2 min at 2500 3 g to prepare platelet-poor plasma. After
1 min pre-incubation at 37°C, platelet aggregation was
induced by 20 mmol/liter adenosine diphosphate (ADP) or
5 mmol/liter thrombin receptor activating peptide (TRAP).
The extent of platelet aggregation was determined after
2 min by light transmittance (PAP-4 platelet aggregometer,
BioData, Horsham, Pennsylvania).
GPIIb/IIIa receptor number and conformation. The
GPIIb/IIIa receptor number and conformation were ana-
lyzed by quantifying the binding of two monoclonal anti-
bodies to GPIIb/IIIa, mAb1 and mAb2 (BioCytex, Mar-
seille, France), that recognize distinct epitopes on the
GPIIb/IIIa receptor (17). The total number of GPIIb/IIIa
receptors can be determined by mAb1, whereas mAb2
recognizes only the unbound GPIIb/IIIa. In the presence of
GPIIb/IIIa antagonists, the mAb2 epitope on the receptor
disappears as a result of a ligand-induced change in the
conformation of GPIIb/IIIa. PRP (20 ml) was incubated
with 45 mg/ml of mAb1 or mAb2 for 20 min at room
temperature. Samples and a tube containing calibration
beads were stained with 20 ml of fluorescein isothiocyanate-
labeled anti-mouse antibody for 10 min and transferred to
gel tubes containing 1 ml of 0.1% paraformaldehyde for
10 min. These gel tubes consisted of a small tube with a
V-shaped bottom containing a small amount of Sephadex
gel. The gel tubes were centrifuged at 850 3 g for 10 min,
which allowed the platelets to penetrate the gel. The
supernatant was poured off, and the gel was washed twice in
phosphate buffered saline (PBS). The tubes were filled with
PBS and stored at 4°C until analyzed (within two weeks).
These gel tubes enable the platelets to be washed and also
provide a suitable storage medium for them. Prior to
analyses, the tubes were centrifuged at 850 3 g for 10 min,
and the supernatant was poured off. The gel-platelet mix
was then re-suspended in the buffer and analyzed by flow
cytometry as described below.
Marker of platelet activation. Platelet activation was
monitored by the expression of the protein CD63 antigen,
which is released to the platelet surface after activation (18).
PRP (20 ml) was incubated with CD63 (BioCytex, Mar-
seille, France) for 20 min at room temperature. A similar
tube was also prepared with the addition of TRAP (5
mmol/liter) 10 min prior to the addition of CD63, which
was used to gate for CD63-positive platelets. Samples were
then stained with a secondary antibody and analyzed by flow
cytometry.
Quantitative fluorescence cytometry. Samples were col-
lected using log forward scatter (FSC), side scatter (SSC)
and fluorescence. A region was drawn around the peak
density of platelets in the FSC versus SSC plot, and this was
used as a gate for analysis of the platelet population. A
histogram marker was drawn around the TRAP-activated
CD63-stained platelets so as to include 95% of all positive
platelets. This was defined as the positive population.
Events from the sample population falling in this region
were considered positive. Calibration beads (BioCytex,
Marseille, France) were also analyzed, and a log plot of
mean fluorescence intensity versus molecules of antibody
was prepared. Flow cytometry was performed on a Becton
Dickinson FACSCalibur flow cytometer and analyzed using
CellQuest software (B & D, Oxford, United Kingdom).
Plasma concentration. The plasma concentration of orbo-
fiban was measured by high-performance liquid chromatog-
raphy/mass spectrometry.
In Vitro Studies
Platelet aggregation. Platelet aggregation was induced
with epinephrine, and a concentration that induced ,35%
platelet aggregation was identified. Platelet aggregation was
performed in the absence and presence of orbofiban at a
concentration (60 nmol/liter, 20 ng/ml) that alone did not
inhibit ADP-induced aggregation (IC50 130 6 10 nmol/
liter, 43 6 3 ng/ml).
Thromboxane production. Signaling through integrins is
accommodated by prior clustering of the receptor (12,19).
Platelet GPIIb/IIIa receptors were clustered using
antibody-coated magnetic beads (20). Briefly, gel-filtered
platelets (5 3 106 platelets) were incubated with 2 3
107 beads (Dynal MPC-E, Oslo, Norway) coated with
CD41, a monoclonal antibody to GPIIIa, in the presence of
orbofiban, abciximab or vehicle for 45 min at room temper-
ature. They were then magnetized for 2 min, snap-frozen,
and stored until the thromboxane B2 levels were measured
by ELISA (R&D Systems, Oxon, United Kingdom). Al-
ternatively, platelets were incubated with 4F8 (BioCytex,
Abbreviations and Acronyms
ADP 5 adenosine diphosphate
ANOVA 5 analysis of variance
FSC 5 forward scatter
GPIIb/IIIa 5 platelet fibrinogen receptor
IV 5 intravenous
MI 5 myocardial infarction
PBS 5 phosphate buffered saline
PRP 5 platelet-rich plasma
SSC 5 side scatter
TRAP 5 thrombin receptor activating peptide
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Marseille, France) without beads, followed by orbofiban,
snap-frozen, and thromboxane B2 levels measured. Note
that CD41 and 4F8 are directed against the GPIIIa subunit,
and as they are not directed at the ligand-binding site, they
do not interfere with the binding of orbofiban or abciximab.
Statistical Analysis
Clinical studies. The data were analyzed by two-way
analysis of variance (ANOVA) of the log transformed data
with a Bonferroni-Dunn post hoc analysis.
In vitro studies. Samples were compared with the control
values using a paired t test.
Materials. Orbofiban was a gift from Dr. Bob Anders, GD
Searle, Skokie, Illinois. The TRAP was from Dr. Pat
Harriott, Queens University, Belfast, UK. All monoclonal
antibodies and gel tubes were from BioCytex, Marseille,
France.
RESULTS
Clinical Studies
Clinical outcomes. The patient characteristics are shown
in Table 1. In the patients with Q wave MI, 58% had their
most recent MI in the inferior wall, 11% anterior, 8%
anterolateral, 6% posterior, 14% were in another location,
and 3% were unknown. There were no differences in
baseline characteristics between the treatment groups. The
numbers of patients completing the study were 76 of 101 on
placebo, 73 of 109 on orbofiban 30 mg bid, 70 of 104 on
40 mg bid, 67 of 104 on 50 mg bid, and 73 of 102 on
orbofiban 50 mg qd. The clinical outcomes of the study are
shown in Table 2. Again, there were no statistical differ-
ences in the outcomes of the different groups, although MI
occurred only in patients receiving orbofiban 50 mg twice
daily or 50 mg daily.
Platelet aggregation and plasma drug levels. Platelet
aggregation was inhibited at all doses of orbofiban (Fig. 1),
although there was poor inhibition at trough (before the
next dose) when the drug was given once daily. The platelet
aggregation data were fitted to a hyperbolic curve and
related to the plasma drug levels. This showed a dose-
response relationship with an IC50 value for inhibition of
ADP-induced aggregation of 29 6 6 ng/ml with a corre-
lation coefficient of 0.84. For TRAP-induced platelet ag-
gregation, the IC50 value was 61 6 18 ng/ml with a
correlation coefficient of 0.75. It is worth noting that only at
the highest dose was the IC50 for these agonists exceeded
throughout the dosing interval (peak 74 6 6 ng/ml, trough
61 6 5 ng/ml).
GPIIb/IIIa receptor number and conformation. Binding
of mAb1, which quantifies receptor number, was unchanged
on any dose of orbofiban throughout the study (Table 3).
However, binding of mAb2 was reduced at all doses of
orbofiban, indicating that the drug altered the conformation
of the receptor. Thus, the ratio of mAb2 to mAb1 binding
fell to about 20% in patients receiving orbofiban 50 mg
twice daily (Fig. 2).
Platelet activation. A significant increase in CD63 antigen
expression occurred in patients receiving active drug
throughout the dosing period (Table 4), and this was dose
dependent (two-way ANOVA, p 5 0.015). Patients on the
placebo showed no change in CD63 antigen expression.
This dose-dependent increase in activation was mainly
accounted for by a significant increase in CD63-positive
Table 1. Baseline Demographics and Characteristics of All Patients, Showing the Percentage of
Patients With Unstable Angina (UA), Q Wave (Q MI) and non–Q Wave (non–Q MI)
Myocardial Infarction at Presentation
Placebo
(n 5 101)
30 mg bid
(n 5 109)
40 mg bid
(n 5 104)
50 mg bid
(n 5 104)
50 mg qd
(n 5 102)
p Value
(x2)
Age 6 SD 58.4 6 11 59.9 6 11 58.7 6 11 60.4 6 11 60.1 6 11 0.637
Male (%) 79 77 81 79 71 0.45
UA 64 58 63 64 60
Q MI 17 23 18 22 17
Non–Q MI 19 19 18 13 24
Table 2. Clinical Outcomes of Treated Patients
Events
Placebo
(n 5 101)
30 mg bid
(n 5 109)
40 mg bid
(n 5 104)
50 mg bid
(n 5 104)
50 mg qd
(n 5 102)
p Value
(x2)
Events (%) 54 67 56 63 54
Cardiac events (%) 46 28 39 34 42
Death 0 1 (3) 0 0 0
MI 0 0 0 3 (9) 4 (10) 0.02
Stroke (hemorrhagic) 0 0 0 0 0
Stroke (nonhemorrhagic) 0 1 (3) 0 1 (3) 0 0.54
Emergency CABG 1 (3) 0 1 (2) 0 0 0.31
Recurrent angina 34 (76) 18 (58) 26 (63) 25 (71) 30 (70) 0.04
Emergency stent/PTCA 4 (9) 2 (6) 1 (2) 2 (6) 2 (5) 0.66
Outcomes are shown as the number of patients and as the percentage of patients with cardiac events in parentheses. Events and cardiac events are a percentage of all patients.
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cells at the lowest dose (30 mg bid, p 5 0.003) of orbofiban
by Bonferroni-Dunn post hoc test.
In Vitro Studies
Aggregation. A low level of epinephrine that induced
minimal platelet aggregation (27 6 9%, n 5 5) was
identified. Orbofiban at a concentration (25 ng/ml) that
resulted in incomplete occupancy of platelet GPIIb/IIIa,
and did not prevent platelet aggregation to ADP
20 mmol/liter, enhanced platelet aggregation to epinephrine
(67 6 16%; p 5 0.04, n 5 5).
Thromboxane production. Clustering of GPIIb/IIIa re-
ceptors with CD41 in the absence of receptor occupancy
induced minimal thromboxane production (1.6 6 2.9 ng/
ml, n 5 6). The addition of orbofiban at a concentration
that will saturate the receptors (3.3 mg/ml) resulted in an
increase in thromboxane to 6.6 6 3.6 ng/ml (n 5 6, p 5
0.03). By contrast, abciximab, a monoclonal antibody that
blocks the ligand binding site, had no significant effect
(2.7 6 0.8 ng/ml, n 5 3, p . 0.05). More marked changes
were seen using 4F8 to cluster the GPIIb/IIIa (Fig. 3), and
the increase in thromboxane induced by orbofiban was
blocked by abciximab (p , 0.05), suggesting that orbofiban
must bind to GPIIb/IIIa to induce platelet activation.
Neither the addition of abciximab to 4F8-bound platelets
nor the addition of orbofiban without 4F8 increased throm-
boxane generation (data not shown).
DISCUSSION
Clinical effectiveness of orbofiban. GPIIb/IIIa is an at-
tractive therapeutic target as antagonists of the receptor
block platelet aggregation to all known agonists, in contrast
to the limited activity of aspirin and clopidogrel. Adminis-
tered as intravenous (IV) agents, GPIIb/IIIa antagonists
have proved effective in a variety of acute coronary syn-
dromes (3). However, oral agents have proved less effective,
and in the case of orbofiban, mortality has increased in
patients on active treatment (8). As shown in this study,
orbofiban suppressed platelet aggregation to ADP and to
TRAP, and this was correlated strongly with plasma drug
levels. However, the degree of inhibition of platelet aggre-
gation and receptor occupancy was far less than the 80%
achieved with IV agents.
GPIIb/IIIa-mediated signaling. We also addressed the
possibility that orbofiban acted as a partial agonist in vivo
and increased platelet activity. Binding of fibrinogen to
GPIIb/IIIa triggers several intracellular events, so-called
outside-in signaling. These include an increase in intracel-
lular Ca21 (13,21), tyrosine phosphorylation (11) and
thromboxane A2 formation (10,21). Outside-in signaling is
dependent on clustering of the receptor (22) (feasible only
with ligands with multiple binding sites such as fibrinogen)
and linkage of the cytoplasmic tail to intracellular proteins
(10). Ligand binding appears to be an additional require-
ment. Thus, small fragments of laminin can induce PGE2
formation if the laminin receptor is first clustered (19).
Figure 1. Percent platelet aggregation (6 SEM) to ADP (20 mmol/liter)
and TRAP (5 mmol/liter) in patients on placebo (n 5 24–31) (diamond);
orbofiban 30 mg bid (n 5 17–29) (solid square); 40 mg bid (n 5 21–29)
(diamond); 50 mg qd (n 5 16–29) (open square); and 50 mg bid (n 5
18–31) (open circle).
Figure 2. The effect of placebo (solid square) and 50 mg bid orbofiban
(solid triangle) on receptor occupancy measured as the ratio of mAb2 to
mAb1 binding (n 5 4–6).
Table 3. Platelet GPIIb/IIIa Receptor Density per Platelet Prior to and on the Final Day of Treatment
Day Time Placebo 50 mg qd 30 mg bid 40 mg bid 50 mg bid
Day 1 Pre-dose 68,016 6 4,400 59,518 6 4,288 82,436 6 14,465 67,799 6 7,355 78,572 6 13,652
(n) (12) (10) (10) (8) (7)
Day 84 Hour 6 73,672 6 5,889 75,671 6 5,670 75,828 6 6,134 73,062 6 5,057 69,985 6 6,649
(n) (10) (5) (4) (6) (5)
Data are expressed as mean (6SEM), with patient numbers in parentheses. There were no significant effects of orbofiban on receptor number.
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Ligand-induced conformational changes. How ligand
binding induces outside-in signaling is unknown, but it may
involve a change in receptor conformation. Many GPIIb/
IIIa antagonists induce conformational changes that are
detected as the appearance of new epitopes (23,24) or, as in
the case of mAb2, the disappearance of an epitope (17). We
show here that orbofiban reduced the binding of mAb2,
although it had no effect on the total number of receptors,
measured as the binding of mAb1. The antibody mAb2
recognizes a site remote from the ligand binding site. This
site disappears upon binding of small ligands, although
mAb2 does not compete directly with the ligand (17). The
findings suggest that mAb2 detects a region that becomes
obscured as a consequence of a ligand-induced change in
conformation. Thus, the disappearance of mAb2 binding in
patients on orbofiban is evidence that the platelet GPIIb/
IIIa has undergone a change in conformation. Ligand-
induced changes in the conformation of GPIIb/IIIa have
been implicated in the partial agonist activity of GPIIb/IIIa
antagonists. For example, Honda and colleagues (13) found
that only compounds inducing conformational changes in
the GPIIIa subunit enhanced the rise in platelet calcium
and aggregation response to platelet agonists.
Platelet activation. We also looked for evidence of in-
creased platelet activation ex vivo. Detecting subtle changes
in platelet activation ex vivo is difficult. Possibly the best
marker is thromboxane A2 formation (4), which was not
possible in this study, because all of the patients were on
aspirin. As an alternative we examined the expression of
CD63 antigen, which is a protein present in the lysosomes
that appears on the surface upon platelet activation (18).
Unlike CD62 antigen, CD63 antigen is highly stable once
expressed (25). Expression of the CD63 antigen was signif-
icantly increased throughout the treatment period in pa-
tients receiving orbofiban.
Orbofiban as a partial agonist. Together with the evi-
dence of a change in conformation, the data suggest that
orbofiban enhanced platelet activity in vivo. This hypothesis
was supported by in vitro experiments demonstrating that
orbofiban acted as a partial agonist. Thus, orbofiban en-
hanced the platelet response to epinephrine. Low concen-
trations of orbofiban insufficient to block all of the platelet
GPIIb/IIIa receptors were used to avoid masking an effect
on platelet aggregation. In a second model, the receptor was
first clustered using monoclonal antibodies to mimic one of
the requirements for signaling via natural ligands. The
addition of the antagonist to clustered receptors resulted in
an increase in thromboxane, a marker of platelet activation.
It may be argued that this type of clustering does not mimic
what happens in vivo. Nevertheless, the experiment dem-
onstrates the potential of orbofiban to induce strong signal-
ing. The increase in thromboxane in the presence of 4F8
was prevented by the monoclonal antibody abciximab,
which binds to the ligand recognition site of GPIIb/IIIa and
prevents orbofiban binding (17). This finding demonstrates
that orbofiban-induced platelet activation is receptor medi-
ated. However, a recent report found that orbofiban can
induce apoptosis in rat cardiomyocytes (26), although it is
not known if this can occur in human platelets.
Clinical significance. Whether the increased platelet ac-
tivity detected in patients on orbofiban is clinically relevant
and contributed to the poor outcome of OPUS-TIMI-16 is
unclear. The ability of orbofiban to enhance platelet aggre-
gation may be important, particularly during the trough
period prior to dosing, when there is insufficient drug to
block platelet aggregation effectively. Platelet activation is
enhanced and plays a major role in the pathogenesis of acute
coronary syndromes, including unstable angina and MI (4).
Platelet microemboli have also been seen in coronary mi-
crovessels of patients suffering sudden cardiac death (7).
Increased platelet activation has also been reported in a
phase II study of sibrafiban, another oral GPIIb/IIIa antag-
onist (27), and a recent report has confirmed the increase in
platelet activation in the phase III orbofiban study (28). It is
possible that in the setting of low-level platelet activation
seen in coronary artery disease, additional activation
through the GPIIb/IIIa receptor may provoke rather than
prevent thrombosis, especially when drug levels are at
trough.
Although there is evidence that abciximab (14,29) and
eptifibatide (30), both of which are clinically effective, also
activate platelets in vitro, these drugs are administered
intravenously and at doses that achieve high levels of
receptor occupancy. Moreover, they are combined with
Figure 3. The effect of orbofiban and abciximab1orbofiban on 4F8-
induced thromboxane formation.
Table 4. Percent Platelets Positive for CD63 (6SEM) During
Treatment With Orbofiban (n 5 32) or Placebo (n 5 12)
Day Time Placebo Orbofiban
Pretreatment 20 6 3.3 23 6 2.5
Day 1 Hour 4 18 6 3.3 31 6 3.7**
Hour 6 17 6 3.1 32 6 3.8**
Day 28 Predose 25 6 6.5 26 6 4.0
Hour 4 30 6 7.3 30 6 4.2
Hour 6 29 6 5.8 28 6 3.9
Day 84 Predose 24 6 4.3 34 6 4.4**
Hour 4 25 6 4.1 35 6 4.3**
Hour 6 23 6 5.8 31 6 4.7*
Results on treatment are compared with the corresponding predose data. *p , 0.05;
**p , 0.01.
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anticoagulants, which have been shown to enhance the
response to a GPIIb/IIIa antagonist in an experimental
model of coronary thrombosis (31). Thus, partial agonism
may not be a problem with IV compounds, because they
maintain stable plasma levels with a high level of blockade,
are supplemented with anticoagulants, and are administered
for only a short period of time.
Conversely, partial agonism combined with either low
dosing or a low trough can lead to an increase in events in
patients treated with an oral GPIIb/IIIa antagonist. The
longer duration of treatment also increases the likelihood of
a patient’s forgetting to take medication, thereby increasing
the chance of a low trough.
In conclusion, the relatively low plasma drug levels and
suboptimal inhibition of platelet aggregation along with a
partial agonist effect may have contributed to the poor
clinical efficacy of orbofiban.
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